This study is recruiting. It focuses on ADHD and currently lists participation information in Italy.
This study is comparing Sustained-Paced Finger Tapping" (Petilli et al., 2018) with ADHD group and Control Group for people with ADHD - Attention Deficit Disorder With Hyperactivity. Participants receive Sustained-Paced Finger Tapping" (Petilli et al., 2018) or ADHD group and Control Group and complete study visits and assessments. Some participants may receive ADHD group and Control Group instead of the study treatment, and direct benefit is not guaranteed.
The official record suggests in-person participation through a hospital, with sites including Associazione "La Nostra Famiglia"-IRCCS "E Medea"-Scientific Hospital for Neurorehabilitation-Unit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation) in Brindisi and Università del Salento in Lecce. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually matching the main diagnosis and having a stable enough treatment background for the study, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
This study may matter because it adds public evidence around adhd. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Italy.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with a control group. Direct benefit is not guaranteed.
This study is sponsored by IRCCS Eugenio Medea. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.